Summary
The antitumor properties of 1-alkylcarbamoyl derivatives of 5-fluorouracil were examined in various mouse tumor systems to select promising compounds for clinical use. Almost all alkylcarbamoyl derivatives were active against various tumors when given by oral administration. Among them, 1-methyl, 1-ethyl, 1-isopropyl, 1-hexyl and 1-octyl carbamoyl derivatives of 5-fluorouracil were moderately or markedly active in six mouse tumor systems tested. However, 1-methyl, 1-ethyl, and 1-isopropyl carbamoyl derivatives were toxic to mice, though not lethal. As a result, 1-hexyl and 1-octyl carbamoyl derivatives were selected as the best candidates for antitumor agents in further study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cline, M. J.: Introduction to chemotherapy. In: Cancer Chemotherapy, p. 1. Philadelphia: Saunders 1971
Fujii, S., Watanabe, S., Yasuda, Y., Suna, S., Unemi, N.: Experimental studies of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207). Anti-tumor activity by the oral administration. Pharmacometrics 7, 1277 (1973)
Fujimoto, S., Akao, T., Itoh, B., Koshizuka, I., Koyano, K. Kitsukawa, Y., Takahashi, M., Minami, T., Ishigami, H., Miyazaki, M., Itoh, K.: Follow-up studies of the gastrointestinal cancer patients treated by the extended oral 5-FU and FT-207 as an adjuvant to surgical treatment. Jpn. J. Cancer Clin. 22, 471 (1976)
Gellhorn, A., Hirschberg, E.: Summary of results and general correlations. Cancer Res. [Suppl.] 3, 1 (1955)
Hahn, R. G., Moertel, C. G., Schutt, A. J., Bruckner, H. W.: A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. Cancer 35, 1031 (1975)
Hoshi, A., Kuretani, K.: Screening methods for antitumor agents. Farumashia 9, 464 (1973)
Hoshi, A., Iigo, M., Nakamura, A., Kuretani, K.: Antitumor activity of benzoyl and benzenesulfonyl derivatives of 5-fluorouracil. Gann 65, 463 (1974)
Hoshi, A., Iigo, M., Yoshida, M., Kuretani, K.: Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration. Gann 66, 673 (1975)
Hoshi, A., Iigo, M., Nakamura, A., Inomata, M., Kuretani, K.: Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil against L1210 leukemia. Chem. Pharm. Bull. (Tokyo) 26, 161 (1978)
Johnson, R. K., Goldin, A.: The clinical impact of screening and other experimental tumor studies. Cancer Treat. Rev. 2, 1 (1975)
Konda, C., Niitani, H., Sakauchi, N., Suzuki, A., Sakai, Y., Sakano, T., Shimoyama, M., Kitahara, T., Kimura, K., Kumaoka, S.: Chemotherapy of cancer with oral administration of N1-(2′-furanidyl)-5-fluorouracil. Jpn. J. Cancer. Clin. 19, 495 (1973)
Ozaki, S., Ike, Y., Mizuno, H., Ishikawa, K., Mori, H.: 5-Fluorouracil derivatives. I. The synthesis of 1-carbamoyl-5-fluorouracils. Bull. Chem. Soc. Jpn. 50 2406 (1977)
Toide, H., Akiyoshi, H., Minato, Y., Okuda, H., Fujii, S.: Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 68, 553 (1977)
Zubrod, C. G.: Quantitative concepts in the clinical study of drugs. Adv. Chemother. 1, 9 (1964)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iigo, M., Hoshi, A., Nakamura, A. et al. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother. Pharmacol. 1, 203–208 (1978). https://doi.org/10.1007/BF00257150
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257150